A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus (HEVRibavirin)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by an acute and rapid deterioration of liver function in a patient with previously well-compensated liver disease owing to the effects of a precipitating event. In this condition two insults act simultaneously, one being the preexisting liver injury (chronic liver disease) and the other acute injury which is responsible for the acute decompensation. HEV being a major factor responsible for this clinical entity and has a very high mortality rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can be an important drug in the treatment of these patients. Therefore the present study is designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF.
Condition or disease
Acute on Chronic Hepatic FailureLiver FailureHepatitis E Infection
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
12 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All ACLF due to HEV
Consent to participate in trial and collection of blood.
Pregnant and nursing mothers.
Other etiologies of ACLF (eg. Alcohol, drugs, reactivation of hepatitis B and hepatitis C, variceal bleeding, surgical intervention and sepsis)
Hepatocellular carcinoma (HCC)
Hepatorenal syndrome (HRS) at admission
Presence of life threatening cardiovascular, respiratory and neurological disease
Acquired Immunodeficiency Syndrome
Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)
Refusal to provide consent to participate in the study